Marinomed Biotech AG · VIE:MARI
Marinomed Biotech — Investor Presentation (December 2020)
14 slides from Marinomed Biotech's investor presentation, December 2020
Slide 1: Marinomed Overview December 2020
Marinomed Overview December 2020
Slide 2: Disclaimer
Disclaimer This presentation (the “Presentation”) was prepared by Marinomed Biotech AG. The information contained in this Presentation has not been independently verified and no representation or warranty expressed or implied is made as to, and no reliance should be placed on, the fairness, accuracy
Slide 3: Marinomed snapshot
Marinomed snapshot A lean biopharmaceutical expert in OTC and Rx therapies Founded in 2006… …Marinomed established two platforms… IPO and EIB platform clinically financing Proven ability to Proven ability of established validated develop revenue continued innovation generating products and IP genera
Slide 4: Record year 2019 and positive outlook 2020
Record year 2019 and positive outlook 2020 Important milestones provide basis for accelerated development going forward €37.4m Phase III COVID-19 Budesolv with strong Increases demand for Financing through IPO results – technology virus blockers and EIB platform validated +31% Free Float 58% Revenue
Slide 5: Marinomed delivers new patent protected technologies enabling innovative therapies
Marinomed delivers new patent protected technologies enabling innovative therapies and unique solutions 5
Slide 6: Marinosolv explained based on Budesolv
Marinosolv® explained based on Budesolv Marinosolv® allows to provide Budesonide in solution offering a competitive edge Suspension Solution Rhinocort Aqua Marinosolv® enabled Budesonide nasal spray Budesonide nasal spray 64µg per dose/spray 10µg per dose/spray Properties USPs Proven Solubility incr
Slide 7: Marinosolv with significant milestones
Marinosolv® with significant milestones Progress as promised with future untapped potential Positive Top-line results Market approval process1 ▪ Budesolv showed a pronounced reduction of ▪ ongoing – generation of stability data allergic nasal symptoms in less than 3 hours ▪ H1/2021 – application for
Slide 8: Budesolv – redefining the market for allergic rhinitis
Budesolv – redefining the market for allergic rhinitis Budesolv has the potential to become a blockbuster product ▪ Target market Allergic Rhinitis $13.0bn New Class ▪ Steroids in Allergic Rhinitis growing 5.4% ▪ First aqueous solution annually from $5.0bn to $8.3bn in 2028 ▪ First compound active a
Slide 9: Tacrosolv – a powerful immunmodulator
Tacrosolv – a powerful immunmodulator Highly potent API with Marinosolv and smart clinical approach for new eye indications Very promising preclinical data1 Risk reduced clinical strategy Dispersion Allergic Conjunctivitis With successful Phase II in allergic conjunctivitis, likely, Phase II for Dry
Slide 10: Carragelose with innovative mode of action
Carragelose® with innovative mode of action Carragelose® blocks viral attachment to cells via an unspecific physical mechanism Mode of action Shortening of symptoms clinically proven ▪ Colds are caused by more than 200 different ▪ 3 Double-blind, placebo-controlled clinical trials respiratory viruse
Slide 11: Carragelose: Innovative applications
Carragelose®: Innovative applications Plannable growth through market entries in the coming years Example of Carragelose® based nasal sprays 15 partners in more than 40 countries Additional growth potential New Existing New markets markets products Carragelose® Goal: all based 100 countries pharmace
Slide 12: Short-term COVID-19 impact on Marinomed
Short-term COVID-19 impact on Marinomed Increased demand for Carragelose® products and some short term delays in trails High demand for Carragelose® products ▪ Close contact with partner producers to increase production ▪ Supply chain management is the main challenge in 2020 Pandemic-related, short-
Slide 13: Positive Outlook 2020
Positive Outlook 2020 Investments in Marinosolv® and commercialisation of Carragelose® COVID-19 boosts demand for virus blocking products ▪ Marinomed’s technology platforms are broadly and excellent positioned ▪ Marinomed is involved in extensive national and international research activities Strong
Slide 14: www.marinomed.com
: Orrarino www.marinomed.com
Marinomed Biotech — Investor Presentation (December 2020) on 6ix